Despite the political and social controversy affiliated with it, the medical community must come to the realization that cannabinoids exist as a ubiquitous signaling system in many organ systems. Our understanding of cannabinoids and how they relate not only to homeostasis but also in disease states must be furthered through research, both clinically and in the laboratory. The identification of the cannabinoid receptors in the early 1990s have provided us with the perfect target of translational research. Already, much has been done with cannabinoids and the nervous system. Here, we explore the implications it has for the gastrointestinal tract. Most therapeutics currently on the market presently target only one aspect of the cannabinoid system. Our main purpose here is to highlight areas of research and potential avenues of discovery that the cannabinoid system has yet to reveal.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11938-016-0111-1 | DOI Listing |
Alzheimers Dement
December 2024
University of Florida College of Medicine, Gainesville, FL, USA.
Background: The presence of Tau pathology is strongly associated with the clinical symptoms and cognitive decline found in Alzheimer's disease (AD), suggesting that targeting pathological tau may be a more effective therapeutic approach. Microglia have been implicated in tauopathies as their activation is strongly related to the progression of tau phosphorylation and aggregation potentially due to dysfunctional lysosomal activity. Cannabinoid type 2 receptors (CB2) are highly expressed in immune cells and upregulated in activated microglia under conditions of neurologic disease, such as AD.
View Article and Find Full Text PDFCurr Top Behav Neurosci
January 2025
Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Cannabis sativa has been used therapeutically since early civilizations, with key cannabinoids Δ-tetrahydrocannabinol (THC) 3.1 and cannabidiol characterized in the 1960s, leading to the discovery of cannabinoid receptors type 1 (CBR) and type 2 (CBR) and the endocannabinoid system (ECS) in the 1990s. The ECS, involving endogenous ligands like 2-arachidonoylglycerol (2-AG) 1.
View Article and Find Full Text PDFeNeuro
January 2025
Program in Neuroscience, University of Maryland Baltimore, Baltimore, MD, 21201.
Cannabinoid receptor-1 (CB1R) signaling in the dorsal striatum regulates the shift from flexible to habitual behavior in instrumental outcome devaluation. Based on prior work establishing individual, sex, and experience-dependent differences in Pavlovian behaviors, we predicted a role for dorsomedial striatum (DMS) CB1R signaling in driving rigid responding in Pavlovian autoshaping and outcome devaluation. We trained male and female Long Evans rats in Pavlovian Lever Autoshaping (PLA).
View Article and Find Full Text PDFInt J Pharm
December 2024
Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, 06100, Sıhhiye, Ankara, Turkey; METU MEMS Center, 06530, Ankara, Turkey. Electronic address:
Rapid progressing non-small cell lung adenocarcinoma (NSCLC) decreases treatment success. Cannabinoids emerge as drug candidates for NSCLC due to their anti-tumoral capabilities. We previously reported the controlled release of Arachidonylcyclopropylamide (ACPA) selectively targeting cannabinoid 1 (CB1) receptor in NSCLC cells in vitro.
View Article and Find Full Text PDFCureus
December 2024
Emergency Medicine, Memorial Healthcare System, Hollywood, USA.
A six-year-old boy presented to the pediatric emergency department following an accidental ingestion of a synthetic cannabinoid. The child ingested an edible product containing tetrahydrocannabinol (THC) and presented with lethargy, altered mental status, and increased muscle tone. The airway was protected, and the patient was breathing spontaneously.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!